Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
155
Participants
Timeline
Start Date
June 1, 2021
Primary Completion Date
July 31, 2025
Study Completion Date
December 31, 2025
Conditions
HNSCC
Interventions
DRUG
Camrelizumab
IV
Trial Locations (1)
100021
Cancer hospital, Chineses Academy of Medical Sciences, Beijing
All Listed Sponsors
lead
Chinese Academy of Medical Sciences
OTHER
NCT04861467 - Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter